title: Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines.
abstract: BACKGROUND
  Many cancers preferentially meet their energy requirements through the glycolytic pathway rather than via the more efficient oxidative phosphorylation pathway. It is thought that this is an important adaptation in cancer malignancy. We investigated whether use of glycolysis for energy production even in the presence of oxygen (known as the Warburg effect) varied between neuroblastoma cell lines with or without MYCN amplification (a key indicator of poor disease outcome in neuroblastoma).
  
  
  METHODS
  We examined ATP and lactate production, oxygen consumption and mitochondrial energisation status for three neuroblastoma cell lines with varying degrees of MYCN amplification and MYCN expression.
  
  
  RESULTS
  We found no correlation between MYCN expression and the Warburg effect in the cell lines investigated.
  
  
  CONCLUSIONS
  Our results suggest preferential use of glycolysis for energy production and MYCN expression may be independent markers of neuroblastoma malignancy in vitro if not in vivo.
authors.affiliation: Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics, Monash University, Wellington Road, CLAYTON, Victoria 3800, Australia. danielle.smith@med.monash.edu.au
authors.forename: Danielle J
authors.initials: DJ
authors.lastname: Smith
authors.forename: Luke R
authors.initials: LR
authors.lastname: Cossins
authors.forename: Irene
authors.initials: I
authors.lastname: Hatzinisiriou
authors.forename: Michelle
authors.initials: M
authors.lastname: Haber
authors.forename: Phillip
authors.initials: P
authors.lastname: Nagley
mesh_terms: D000255:Adenosine Triphosphate / Q000096:biosynthesis*; D045744:Cell Line, Tumor; D005784:Gene Amplification; D016259:Genes, myc / Q000235:genetics; D006019:Glycolysis / Q000235:genetics / Q000502:physiology*; D006801:Humans; D019344:Lactic Acid / Q000096:biosynthesis*; D053078:Membrane Potential, Mitochondrial / Q000502:physiology; D000071447:N-Myc Proto-Oncogene Protein; D009363:Neoplasm Proteins / Q000378:metabolism*; D009447:Neuroblastoma / Q000235:genetics / Q000378:metabolism*; D009687:Nuclear Proteins / Q000378:metabolism*; D015513:Oncogene Proteins / Q000378:metabolism*; D010101:Oxygen Consumption / Q000502:physiology; D010641:Phenotype
chemical_list: C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D019344:Lactic Acid; D000255:Adenosine Triphosphate
references.citation: Oncogene. 1995 Aug 3;11(3):485-91
references.pmid: 7630632
references.citation: Oncogene. 1990 Dec;5(12):1821-7
references.pmid: 2284101
references.citation: Cancer. 1998 Sep 1;83(5):918-24
references.pmid: 9731895
references.citation: Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36
references.pmid: 16971499
references.citation: Science. 1984 Jun 8;224(4653):1121-4
references.pmid: 6719137
references.citation: Nat Rev Cancer. 2004 Nov;4(11):891-9
references.pmid: 15516961
references.citation: Cancer Res. 2004 Jun 1;64(11):3892-9
references.pmid: 15172999
references.citation: Cancer Res. 2002 Nov 15;62(22):6674-81
references.pmid: 12438266
references.citation: Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1166-71
references.pmid: 9037024
references.citation: Lancet. 2007 Jun 23;369(9579):2106-20
references.pmid: 17586306
references.citation: Anticancer Res. 2006 Sep-Oct;26(5A):3467-72
references.pmid: 17094468
references.citation: Cancer Res. 1991 Feb 1;51(3):794-8
references.pmid: 1846317
references.citation: Oncogene. 2000 Dec 27;19(56):6651-9
references.pmid: 11426651
references.citation: Neoplasia. 2003 Mar-Apr;5(2):135-45
references.pmid: 12659686
references.citation: J Natl Cancer Inst. 1976 Sep;57(3):683-95
references.pmid: 62055
references.citation: J Natl Cancer Inst. 2003 Sep 17;95(18):1394-403
references.pmid: 13130115
references.citation: Biochim Biophys Acta. 1996 Mar 27;1311(1):1-4
references.pmid: 8603096
references.citation: Cancer Res. 1987 Oct 1;47(19):5207-12
references.pmid: 3040240
references.citation: Cancer. 2002 Feb 15;94(4):921-8
references.pmid: 11920459
references.citation: Cancer Res. 2000 May 1;60(9):2483-7
references.pmid: 10811128
references.citation: J Clin Oncol. 2000 Nov 1;18(21):3604-13
references.pmid: 11054433
references.citation: Exp Cell Res. 2001 Jan 1;262(1):8-16
references.pmid: 11120600
references.citation: J Clin Oncol. 1996 Feb;14(2):405-14
references.pmid: 8636750
references.citation: Cancer. 2001 Mar 1;91(5):889-99
references.pmid: 11251940
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5992-7
references.pmid: 15840712
references.citation: Cancer. 1988 Sep 15;62(6):1074-8
references.pmid: 3261622
references.citation: Oncogene. 1988 Apr;2(4):399-402
references.pmid: 2834684
references.citation: Cell Death Differ. 2003 Feb;10(2):163-74
references.pmid: 12700644
references.citation: J Bioenerg Biomembr. 2007 Jun;39(3):251-7
references.pmid: 17624581
references.citation: Prog Clin Biol Res. 1988;271:265-76
references.pmid: 2900511
references.citation: Nature. 1983 Sep 15-21;305(5931):245-8
references.pmid: 6888561
references.citation: J Clin Oncol. 2001 Jul 15;19(14):3397-405
references.pmid: 11454888
references.citation: EMBO J. 1997 Jun 2;16(11):2985-95
references.pmid: 9214616
references.citation: Cancer Res. 2006 Mar 1;66(5):2826-33
references.pmid: 16510605
references.citation: Biochemistry (Mosc). 1998 Feb;63(2):235-8
references.pmid: 9526120
references.citation: J Clin Oncol. 1998 Oct;16(10):3286-94
references.pmid: 9779703
references.citation: Carcinogenesis. 2002 May;23(5):759-68
references.pmid: 12016148
references.citation: EMBO J. 2001 Mar 15;20(6):1383-93
references.pmid: 11250904
references.citation: J Natl Cancer Inst. 1983 Oct;71(4):741-7
references.pmid: 6137586
references.citation: Cancer Res. 1986 Aug;46(8):4139-42
references.pmid: 3731081
references.citation: Med Pediatr Oncol. 2000 Dec;35(6):585-9
references.pmid: 11107123